NDMA is a probable human carcinogen, a substance that could cause cancer, the FDA said in April 2020, when the agency asked ...

This lawsuit concerns GSK’s fraud on the federal and state governments and the money spent on ranitidine products by governments because of that fraud. Whether ranitidine increases the risk of cancer ...

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

An over-the-counter medication sold today as Zantac 360 by Sanofi has a different ... and pharmacies pulled the products from their shelves. The next year, the F.D.A. recommended that the drug ...

Only two commercial ranitidine products were assessed for NDMA content via analysis. Powdered samples (100 to 500 mg) were introduced to 10 mL headspace vials for headspace analysis without ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

This came after studies revealed that ranitidine products might have unhealthy levels of NDMA, a known probable carcinogen that can lead to the development of cancer in users. While former Zantac ...

Corrects headline to say 'settlements' instead of 'settlement' British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.